Radiotherapy

Oncology·MeSH: Recurrence

24 drugs in development·7 companies·4 clinical trials

Drug Pipeline by Phase

Phase 3(3)

Phase 2(16)

Drug	Company
Abiraterone Acetate	ENANTA PHARMACEUTICALS INC (ENTA)
aglatimagene besadenovec	Candel Therapeutics, Inc. (CADL)
aglatimagene besadenovec + valacyclovir	Candel Therapeutics, Inc. (CADL)
Bicalutamide	Janux Therapeutics, Inc. (JANX)
Bicalutamide	ENANTA PHARMACEUTICALS INC (ENTA)
Degarelix	Janux Therapeutics, Inc. (JANX)
Degarelix	ENANTA PHARMACEUTICALS INC (ENTA)
Degarelix	Myovant Sciences Ltd. (MYOV)
Degarelix	Royalty Pharma plc (RPRX)
Flutamide	ENANTA PHARMACEUTICALS INC (ENTA)
Flutamide	Janux Therapeutics, Inc. (JANX)
Goserelin Acetate	Janux Therapeutics, Inc. (JANX)
Methylphenidate	Janux Therapeutics, Inc. (JANX)
Methylphenidate	Royalty Pharma plc (RPRX)
Nilutamide	Janux Therapeutics, Inc. (JANX)
Nilutamide	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 1(2)

Drug	Company
ADXS-504	Ayala Pharmaceuticals, Inc. (ADXS)
nbtxr3	Nanobiotix S.A. (NBTX)

Phase 4(3)

BioSniper tracks 24 drugs in development for Radiotherapy across 7 companies.

There are 4 clinical trials targeting Radiotherapy tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.